New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 18, 2012
08:33 EDTFLMLFlamel announces FDA acceptance of NDA for undisclosed hospital-based product
Flamel Technologies SA announced that the U.S. FDA has accepted the company's New Drug Application, or NDA, for an undisclosed hospital-based product. Flamel has received a Prescription Drug User Fee Act, or PDUFA, date, the target date for the FDA to complete its review of the NDA, of May 31, 2013. For competitive reasons, the Company has decided not to identify the product at this time, but intends to provide additional information at a later date. Flamel believes that the product could have a significant impact on the company's revenue generation and favorably impact its progression to profitability. If approved by the FDA, the product is expected to generate approximately $25M-$35M or more in peak annual revenues, subject to the company being able to market and price the product successfully, of which there can be no assurance.
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:47 EDTFLMLFlamel Technologies pullback a buying opportunity, says Summer Street
Subscribe for More Information
08:33 EDTFLMLFlamel Technologies transfers intangible property to Irish-based subsidiary
Flamel Technologies announced that it is moving all intangible property from its French entity to its Irish-based entity as a part of a global reorganization. The intangible property includes patents on its drug delivery platform technologies, clinical data sets and other intangible assets related to its pipeline of proprietary products in development. Flamel's proprietary drug delivery platforms include its Micropump and Medusa platforms. The company anticipates the transfer will result in a one-time tax payment of approximately $14M to the French government. The transfer of these assets is effectively immediately.
December 10, 2014
10:27 EDTFLMLFlamel Technologies management to meet with Roth Capital
Subscribe for More Information
December 8, 2014
07:45 EDTFLMLFlamel Technologies price target raised to $29 from $21 at SunTrust
SunTrust increased its price target on Flamel after meeting with the company's CEO, as the firm now expects the company to raise the price of its Bloxiverz drug next year beyond the firm's previous outlook. SunTrust keeps a Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use